Latest Hotspot

Glenmark Ichnos Sciences Exhibits Early-Stage Results of Cancer Drug Candidate ISB 2001 at 2024 AACR Conference

11 April 2024
3 min read

At the American Association for Cancer Research's annual meeting in 2024, a collaborative venture known as Ichnos Glenmark Innovation, which combines the expertise of Ichnos Sciences Inc.—a worldwide, complete clinical-stage biotechnology firm focused on the creation of multispecifics™ for cancer treatment—and Glenmark Pharmaceuticals Ltd., publicly disclosed early-stage research findings for their cancer-fighting candidate, ISB 2001. This oral presentation outlined the preclinical achievements of ISB 2001, which is now undergoing a Phase I clinical study targeting relapsed and refractory multiple myeloma (r/r MM).

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The verbal exposition presented data on the efficacy of ISB 2001, demonstrating its potential in treating multiple myeloma (MM) within bone marrow samples taken from subjects at initial diagnosis or those enduring relapsed/refractory MM after undergoing various therapy regimens, including those who have shown resistance to therapies targeting CD38 and BCMA. This foundational research highlights the potential capacity of the ISB 2001 trispecific antibody to attack BCMA, CD38 on multiple myeloma cells, and CD3 on T lymphocytes. It underscores the commitment of IGI to contribute to the battle against resistant forms of MM.

"At the AACR conference, we are excited to discuss the early-stage results associated with ISB 2001," expressed Lida Pacaud, MD, the Chief Medical Officer at Ichnos Glenmark Innovation. "The progression of ISB 2001 is of unique importance to our team as it symbolizes the application of our state-of-the-art BEAT antibody engineering platform. This key technology underpins our innovative strategy to create novel therapies addressing hematologic malignancies and solid neoplasms."

Marked as a pioneering T cell-redirecting antibody, ISB 2001 concurrently engages BCMA and CD38 on MM cells. Crafted using the BEAT technique, this proprietary development framework ensures comprehensive adaptability and the capability to produce full-length multispecific antibodies efficiently. ISB 2001 fuses three specialized antigen-recognition domains, with distinct targets: one arm engages with the epsilon chain of CD3 on T lymphocytes, while the remaining arms attach to BCMA and CD38 on MM cells. Moreover, the antibody's Fc region has been ingeniously muted to reduce effector functions of the immune system.

ISB 2001 has the novel function of steering CD3+ T cells to eradicate cancer cells presenting varying levels of both BCMA and CD38. The dual targeting of two tumor-specific antigens affords ISB 2001 improved specificity in adhering to MM cells by leveraging increased binding strength due to enhanced avidity..

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of April 9, 2024, there are 2 investigational drugs for the BCMA and CD3 and CD38 target, including 2 indications, 2 R&D institutions involved, with related clinical trials reaching 16, and as many as 3718 patents.

ISB-2001 is a trispecific antibody drug being developed by Ichnos Sciences, Inc. for the treatment of multiple myeloma. It targets three proteins, BCMA, CD3, and CD38, and is currently in Phase 1 of clinical development. The drug has been designated as an orphan drug, indicating its potential to address a rare disease. Further research and clinical trials will be needed to determine the drug's efficacy and safety profile.

图形用户界面, 文本, 应用程序

描述已自动生成

Summary of Global Clinical Trial Failures in January 2024
Drug Highlight
6 min read
Summary of Global Clinical Trial Failures in January 2024
11 April 2024
The failure of clinical trials can stem from multiple factors. One study suggests that 90% of drug development clinical failures may be attributed to four reasons: lack of clinical efficacy (40%-50%), uncontrollable toxicity (30%), poor pharmacokinetic properties (10%-15%), and absence of commercial demand or poor strategic planning (10%).
Read →
Mabwell's Subsidiary T-mab Gets Approval for Denosumab Injection from National Medical Agency
Latest Hotspot
3 min read
Mabwell's Subsidiary T-mab Gets Approval for Denosumab Injection from National Medical Agency
11 April 2024
Mabwell has declared that its fully-owned subsidiary, T-mab, has successfully received the green light for its Denosumab Injection from the National Medical Products Administration.
Read →
Molecular Glue Decoded: The Next Big Trend in the Small Molecule Drug Arena
Advanced Tech.
17 min read
Molecular Glue Decoded: The Next Big Trend in the Small Molecule Drug Arena
11 April 2024
As the potential of molecular glue technology becomes increasingly apparent, pharmaceutical companies are beginning to invest more heavily in this area.
Read →
HLX14 Biosimilar Meets Goals in Phase 3 Trial Against Prolia® and Xgeva®
Latest Hotspot
3 min read
HLX14 Biosimilar Meets Goals in Phase 3 Trial Against Prolia® and Xgeva®
11 April 2024
Primary Objectives Achieved in Stage 3 Trial for HLX14, a Biosimilar Contender to Prolia® and Xgeva® (denosumab).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.